(Q55044207)
Statements
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond (English)
Susan O'Brien
1 reference
Elias Jabbour
1 reference
Francis Giles
1 reference
Jorge Cortes
1 reference
Elias Jabbour
Francis Giles
Hagop Kantarijan